Literature DB >> 2567191

Peripheral blood stem cell autotransplantation in treatment of childhood cancer.

T Watanabe1, Y Takaue, Y Kawano, T Koyama, M A Huq, T Shimokawa, T Ninomiya, Y Aga, T Inai, M Hino.   

Abstract

The levels of circulating hematopoietic progenitor cells were measured sequentially in eight children receiving chemotherapy for acute leukemia or neuroblastoma. Significant increases in the progenitor levels (up to 50-fold in CFU-GM numbers) were observed during post-chemotherapy cytopenia in all cases, but differences among individuals in the kinetics of recovery of less committed progenitors (CFU-mix) contrasted with the synchronized-mode of expansion of committed progenitors (CFU-GM). Peripheral blood cells were collected by repeated continuous-flow leukaphereses from three of the children during post-chemotherapy expansion of the progenitor pool and were cryopreserved after fractionation procedures. Infusion of these stored cells into the patients after marrow-ablative chemotherapy established trilineage hematopoiesis. This use of stem cell rescue should be useful as an alternative to bone marrow transplantation and extends the application of cure-oriented salvage therapy to childhood cancers.

Entities:  

Mesh:

Year:  1989        PMID: 2567191

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Kawasaki-like disease in early course of acute monocytic leukaemia.

Authors:  H Akita; S Matsuoka; Y Takahashi; T Watanabe; Y Takaue; Y Kuroda
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

2.  Circulating hematopoietic progenitors in patients with primary lung cancer.

Authors:  E Shimizu; J N Mukai; Y Takaue; T Ogura
Journal:  Jpn J Cancer Res       Date:  1990-12

3.  Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas.

Authors:  C R Pinkerton; J Groot-Loonen; A Barrett; S T Meller; D Tait; S Ashley; T J McElwain
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.